University of California, Davis
Welcome,         Profile    Billing    Logout  
 230 Trials 
275 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kelly, Karen
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Active, not recruiting
3
440
US
Infant Formula
Aussie Bubs, Inc.
Infant Development
04/25
04/25
NCT05412030: A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Active, not recruiting
2
472
US
AFX3772, Prevnar 13, PCV13, Prevnar 20, PCV20
GlaxoSmithKline, Affinivax, Inc.
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
07/26
07/26
NCT03474497: UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Recruiting
1/2
45
US
IL-2, Pembrolizumab, Radiotherapy, Radiation Therapy
Megan Daly, MD, Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
12/23
12/23
NCT02599454: Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Active, not recruiting
1
20
US
Atezolizumab, MPDL3280A, Stereotactic Body Radiation Therapy, SBRT
Megan Daly, MD, Genentech, Inc.
Stage I Non-Small Cell Lung Cancer
01/20
12/23
Kim, Edward S
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
VIRAGE, NCT05673811: Study of Nab-Paclitaxel and Gemcitabine and Plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer

Active, not recruiting
2
96
Europe, US
Nab-paclitaxel, Gemcitabine, VCN-01
Theriva Biologics SL
Pancreatic Adenocarcinoma, Metastatic
04/25
04/25
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
NCT03695250: BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Terminated
1/2
8
US
IDO1 Inhibitor BMS-986205, BMS 986205, BMS-986205, BMS986205, IDO-1 Inhibitor BMS-986205, Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205, ONO-7701, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Edward Kim, Bristol-Myers Squibb, National Cancer Institute (NCI)
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
11/20
03/21
ARYA-1, NCT04502082: Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma

Terminated
1/2
6
US
ET140203 autologous T cell product
Eureka Therapeutics Inc.
Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer
06/23
06/23
NCT04050085: SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Completed
1
6
US
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
University of California, Davis, National Cancer Institute (NCI), Bristol-Myers Squibb, Dynavax Technologies Corporation
Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/21
05/22
Creinin, Mitchell D
NCT04457076: Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

Not yet recruiting
3
1525
US
LevoCept
Sebela Women's Health Inc., PRA Health Sciences
Contraception, Women at Risk for Pregnancy
01/29
01/31
NCT06127199: Contraceptive Efficacy Study of Ovaprene

Recruiting
N/A
656
US
Ovaprene
Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception
06/25
09/25
McDonald, Craig M
HOPE-3, NCT05126758: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Active, not recruiting
3
104
US
Deramiocel (CAP-1002), Cardiosphere-Derived Cells (CDCs), Placebo
Capricor Inc.
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
12/25
12/27
ENVISION, NCT05881408 / 2020-002372-13: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Recruiting
3
148
Europe, Japan, US, RoW
delandistrogene moxeparvovec, SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS, placebo
Sarepta Therapeutics, Inc., Hoffmann-La Roche
Duchenne Muscular Dystrophy
05/27
06/28
HOPE-2-OLE, NCT04428476: Open-label Extension of the HOPE-2 Trial

Active, not recruiting
2
13
US
Deramiocel (CAP-1002), Allogeneic Cardiosphere-Derived Cells
Capricor Inc.
Duchenne Muscular Dystrophy
02/22
03/26
MOMENTUM, NCT04004065 / 2019-000601-77: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Checkmark From MOMENTUM trial for DMD
May 2021 - May 2021: From MOMENTUM trial for DMD
Checkmark Interim data from the MOMENTUM study
Dec 2020 - Dec 2020: Interim data from the MOMENTUM study
Checkmark Data from MOMENTUM trial for Duchenne muscular dystrophy
More
Active, not recruiting
2
62
Europe, Canada, US
Vesleteplirsen, SRP-5051
Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy
10/23
01/29
NCT06138639: A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Recruiting
1/2
43
Canada, US
SGT-003
Solid Biosciences Inc.
Duchenne Muscular Dystrophy
05/27
05/31
NCT03863119: Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy

Available
N/A
Canada, US, RoW
Vamorolone
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy
 
 
NCT04475926: A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Recruiting
N/A
241
Europe, Canada, US, RoW
Sarepta Therapeutics, Inc.
Limb-girdle Muscular Dystrophy
04/30
04/30
White, Ralph W deVere
LeAAPS, NCT05478304: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Recruiting
N/A
6500
Europe, Canada, US
AtriClip LAA Exclusion System
AtriCure, Inc., Population Health Research Institute
Ischemic Stroke, Systemic Embolism
12/31
04/32
Bowlus, Christopher L
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
251
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
SPRING, NCT04595825 / 2019-002945-39: CM-101 in PSC Patients -The Study

Active, not recruiting
2
68
Europe, US, RoW
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
ChemomAb Ltd., ChemomAb Ltd
Primary Sclerosing Cholangitis
09/24
09/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Not yet recruiting
2
87
US
LB-P8 low-dose, LB-P8 high-dose, Placebo
LISCure Biosciences
Primary Sclerosing Cholangitis (PSC)
03/28
02/29
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
Armstrong, April W
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Recruiting
2
60
Canada, US
Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo
Apollo Therapeutics Ltd
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
02/25
06/25
Apperson, Michelle
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Recruiting
3
2060
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
Richman, David
RESET-MG, NCT06359041: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Recruiting
1/2
12
US
CABA-201
Cabaletta Bio
Generalized Myasthenia Gravis (gMG)
09/29
09/29
NCT05451212: Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

Recruiting
1
24
US
MuSK-CAART
Cabaletta Bio
MuSK Myasthenia Gravis
10/28
10/28
NCT00704925: Treatment of Lambert-Eaton Syndrome With 3,4 DAP

No Longer Available
N/A
US
3, 4 DAP, 3,4 diaminopyridine
David P. Richman, MD, Jacobus Pharmaceutical
Lambert Eaton Myasthenic Syndrome
 
 
Sood, Namita
ARTISAN, NCT05203510: A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Recruiting
4
50
US
Parenteral Treprostinil, Remodulin, Oral Treprostinil, Orenitram
United Therapeutics, Lung Biotechnology PBC
Pulmonary Arterial Hypertension
12/25
12/27
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
IMPAHCT-FUL, NCT05557942 / 2021-006864-25: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension

Terminated
3
186
Europe, Canada, US, RoW
AV-101
Aerovate Therapeutics, Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension
08/24
08/24
NCT05983250: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Recruiting
3
152
Canada, US
TNX-103, Placebo
Tenax Therapeutics, Inc., Medpace, Inc., Northwestern University
Pulmonary Hypertension
03/27
07/27
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
ASCENT, NCT06129240: An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Recruiting
N/A
60
US
LIQ861
Liquidia Technologies, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
07/26
10/26
IPF-PRO, NCT01915511: Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Checkmark
Oct 2015 - Oct 2015: 
Recruiting
N/A
3000
US
Duke University, Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
01/28
01/28
Underwood, Mark
IMPRINT, NCT02457338: Infant Microbiota and Probiotic Intake Study

Active, not recruiting
N/A
120
US
Bifidobacterium, B. infantis
University of California, Davis, Evolve BioSystems, Inc.
Healthy
07/16
06/27
Pan, Chong-xian
NCT05687721: Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

Not yet recruiting
1/2
29
US
copanlisib, Avelumab
VA Office of Research and Development, Bayer
Advanced Urothelial Carcinoma
12/28
06/29
Liu, Albert
PILLAR, NCT05374525: A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

Completed
4
201
US
APRETUDE, Cabotegravir OLI
ViiV Healthcare
HIV Infections
08/24
08/24
NCT06631365: PrEPsmart 2-1-1 Pilot

Recruiting
2
60
US
PrEPsmart mobile app, Truvada, Emtricitabine, Tenofovir disoproxil fumarate
Public Health Foundation Enterprises, Inc., Gilead Sciences
HIV-1-infection
01/25
04/25
NCT05979714: The Cheeky Study: A Novel Delivery System for CAB-RPV LA

Active, not recruiting
N/A
50
US
Patient-centered injection site, Patient-centered adherence support, Provider education, Improved clinic communication strategies
Public Health Foundation Enterprises, Inc., ViiV Healthcare, San Francisco Department of Public Health, Lyon-Martin Community Health Services
HIV Infections
12/24
12/24
Steinberg, Francene M
FID, NCT06086145: Biomarker-estimated Flavanol Intake in Davis

Recruiting
N/A
200
US
No intervention
University of California, Davis, Mars, Inc.
Adults
09/25
09/25
NCT05701657: Nutrition for Precision Health, Powered by the All of Us

Recruiting
N/A
8000
US
Diet A, Diet B, Diet C, Liquid Mixed Meal Tolerance Test, LMMTT, Diet-Specific Mixed Meal Tolerance Test, Diet-Specific MMTT
RTI International, National Institutes of Health (NIH), University of North Carolina, Chapel Hill, Northwestern University, Illinois Institute of Technology, University of Chicago, Pennington Biomedical Research Center, Louisiana State University Health Sciences Center in New Orleans, University of California, Davis, University of California, Los Angeles, Cedars-Sinai Medical Center, University of Alabama at Birmingham, Tufts University, Massachusetts General Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), City University of New York, School of Public Health, Mayo Clinic, University of California, San Diego, University of Hawaii, Vanderbilt University Medical Center, National Heart, Lung, and Blood Institute (NHLBI), National Center for Complementary and Integrative Health (NCCIH), National Institute of Drug Abuse, Public Health Informatics Computational and Operations Research, University of Southern California, Cornell University, University of Alabama, Tuscaloosa, North Carolina State University, University of North Carolina, Charlotte, Duke University, Stevens Institute of Technology, Purdue University, United States Military Academy at West Point, USDA, Western Human Nutrition Research Center, North Carolina Central University, Wake Forest University Health Sciences, Boston University, Children's Hospital of Richmond, Virginia Commonwealth University, Verily Life Sciences LLC, Indiana University, Fred Hutchinson Cancer Center, Columbia University, University of Pennsylvania
Nutrition, Health, Dietary Habits
12/26
01/27
Kim, Kee
NCT03118505: A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions

Active, not recruiting
N/A
100
US
Infuse Bone Graft, Medtronic DBM
Medtronic Spinal and Biologics
Multi-Level Degenerative Lumbosacral Spinal Conditions
04/26
12/26
TLIF, NCT04073563: Transforaminal Lumbar Interbody Fusion

Recruiting
N/A
1017
US, RoW
Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems
Medtronic Spinal and Biologics
Degenerative Disease of the Lumbosacral Spine
04/26
04/28
NCT05856370: The Ailliance Post-Market Clinical Study

Recruiting
N/A
1000
US
Follow-up schedule: pre-operative baseline up to 24-months post-procedure
Medtronic Spinal and Biologics, Medtronic Bakken Research Center
Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma, Spinal Tumor Case
05/31
05/31
Henderson, Paul
NCT05986851: Azeliragon in MGMT Unmethylated Glioblastoma

Active, not recruiting
2
30
US
Azeliragon
Cantex Pharmaceuticals, Medpace, Inc.
Glioblastoma
09/24
06/25
Sokol, Eric
CELLEBRATE, NCT03104517 / 2016-002635-15: Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

Recruiting
3
96
Europe, US
AMDC-USR (iltamiocel), Placebo
Cook MyoSite
Stress Urinary Incontinence
01/25
02/26
NCT04758247: Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms

Completed
N/A
12
US
TheraNova Neuromodulation System
Theranova, L.L.C.
Overactive Bladder
12/23
12/23
NCT05162833: Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms

Completed
N/A
3
US
TheraNova Neuromodulation Device
Theranova, L.L.C.
Overactive Bladder
12/23
12/23
Daly, Megan E
NCT03474497: UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Recruiting
1/2
45
US
IL-2, Pembrolizumab, Radiotherapy, Radiation Therapy
Megan Daly, MD, Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
12/23
12/23
Abedi, Mehrdad
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/25
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001)

Active, not recruiting
2
25
US
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network
Sickle Cell Disease
05/26
05/26
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
Starlight-1, NCT06343311: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Recruiting
1/2
21
US
EB103
Estrella Biopharma, Inc., Eureka Therapeutics Inc.
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, HIV Associated Lymphoma, CNS Lymphoma, High-grade B-cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
12/26
12/27
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Hourglass Jul 2024 - Dec 2024 : Submission in UK for adult r/r B-ALL
Active, not recruiting
1/2
153
NA
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
05/25
05/25
LIMBER-TREG108, NCT05423691: Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Recruiting
1
24
US
CK0804
Cellenkos, Inc.
Myelofibrosis
04/24
04/24
OGFT001-001, NCT03802695: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Recruiting
1
186
US
OrcaGraft (Orca-Q)
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia
04/26
04/28
NEXICART-2, NCT06097832: Study of NXC-201 CAR-T in Patients with Light Chain (AL) Amyloidosis

Recruiting
1
40
US
NXC-201 CAR-T, HBI0101 CAR-T
Nexcella Inc., Immix Biopharma, Inc.
Light Chain (AL) Amyloidosis
12/26
01/39
NCT04422912: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting
1
55
US
DSG3-CAART or CABA-201
Cabaletta Bio
Pemphigus Vulgaris
01/29
01/29
Adams, Sean H
NCT05701657: Nutrition for Precision Health, Powered by the All of Us

Recruiting
N/A
8000
US
Diet A, Diet B, Diet C, Liquid Mixed Meal Tolerance Test, LMMTT, Diet-Specific Mixed Meal Tolerance Test, Diet-Specific MMTT
RTI International, National Institutes of Health (NIH), University of North Carolina, Chapel Hill, Northwestern University, Illinois Institute of Technology, University of Chicago, Pennington Biomedical Research Center, Louisiana State University Health Sciences Center in New Orleans, University of California, Davis, University of California, Los Angeles, Cedars-Sinai Medical Center, University of Alabama at Birmingham, Tufts University, Massachusetts General Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), City University of New York, School of Public Health, Mayo Clinic, University of California, San Diego, University of Hawaii, Vanderbilt University Medical Center, National Heart, Lung, and Blood Institute (NHLBI), National Center for Complementary and Integrative Health (NCCIH), National Institute of Drug Abuse, Public Health Informatics Computational and Operations Research, University of Southern California, Cornell University, University of Alabama, Tuscaloosa, North Carolina State University, University of North Carolina, Charlotte, Duke University, Stevens Institute of Technology, Purdue University, United States Military Academy at West Point, USDA, Western Human Nutrition Research Center, North Carolina Central University, Wake Forest University Health Sciences, Boston University, Children's Hospital of Richmond, Virginia Commonwealth University, Verily Life Sciences LLC, Indiana University, Fred Hutchinson Cancer Center, Columbia University, University of Pennsylvania
Nutrition, Health, Dietary Habits
12/26
01/27
Adams, John
NCT05973006: Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

Completed
3
400
US
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, NVX-CoV2601, Prototype/XBB.1.5 Bivalent Vaccine (5 µg), Omicron XBB.1.5 (sub-variant)SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
04/24
09/24
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension

Enrolling by invitation
3
1400
Europe, Canada, US, RoW
lorundrostat, Placebo
Mineralys Therapeutics Inc.
Hypertension
12/25
12/26
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Active, not recruiting
2
285
US
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
01/25
02/25
LIMIT, NCT05094791: Lateralization After IntraMedullary Nailing of InterTrochanteric Hip Fractures, Clinical and Radiographic Outcomes

Completed
N/A
60
US
Telescoping Lag Screw, Arthrex Hip Nail, Standard lag Screw, Zimmer Natural Nail, Standard lag screw with addition of worm screw, Smith and Nephew TRIGEN INTERTAN
Prisma Health-Upstate, Arthrex, Inc.
Intertrochanteric Fractures
02/24
02/24
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting
N/A
3465
US
Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test
Biotheranostics, Inc.
Breast Cancer
12/28
12/28
Castro, Diana
DEVOTE, NCT04089566 / 2019-002663-10: Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

Completed
3
145
Europe, Canada, Japan, US, RoW
Nusinersen, BIIB058
Biogen
Muscular Atrophy, Spinal
02/24
05/24
ASCEND, NCT05067790 / 2021-001294-23: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam

Recruiting
3
45
Europe, Japan, US
Nusinersen, BIIB058, Spinraza
Biogen
Spinal Muscular Atrophy
06/27
06/27
ARGX-113-2207, NCT06392386: A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age with Generalized Myasthenia Gravis

Recruiting
2/3
12
Europe, US, RoW
Efgartigimod PH20 SC
argenx
Generalized Myasthenia Gravis
09/26
09/26
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
NCT06579352: Expanded Access Study of UC-MSC in DMD Patients

Available
N/A
US
Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)
MED Institute Inc., Signature Biologics
Duchenne Muscular Dystrophy
 
 
NCT03863119: Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy

Available
N/A
Canada, US, RoW
Vamorolone
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy
 
 
NCT06564974: Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy.

Recruiting
N/A
250
US
Vamorolone, AGAMREE®
Catalyst Pharmaceuticals, Inc.
Duchenne Muscular Dystrophy
09/30
11/30
Oskarsson, Bjorn
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS

Recruiting
2/3
230
Canada, US
MN-166, ibudilast, placebo
MediciNova
Amyotrophic Lateral Sclerosis
12/25
12/26
NCT05517603: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

Completed
1/2
25
US
AJ201, JM17, Placebo
AnnJi Pharmaceutical Co., Ltd.
Spinal and Bulbar Muscular Atrophy, Kennedy's Disease
04/24
04/24
ALSpire, NCT04494256 / 2020-000207-36: A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

Terminated
1/2
99
Europe, Canada, US
BIIB105, Placebo
Biogen, Biogen Idec Research Limited
Amyotrophic Lateral Sclerosis
08/24
08/24
SEANOBI-ALS, NCT06743776: Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

Available
N/A
NA
MN-166
Mayo Clinic, WideTrial, Inc., MediciNova, National Institute of Neurological Disorders and Stroke (NINDS)
ALS
 
 
Greenhalgh, David
NCT05084183: Evaluation of the Effectiveness of PermeaDerm® (PD) as Compared to Mepilex Ag®

Recruiting
N/A
68
US
PermeaDerm®, Mepilex Ag
Stedical Scientific, Inc.
Thermal Burn
11/22
11/23
Wang-Polagruto, Janice
NCT03118505: A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions

Active, not recruiting
N/A
100
US
Infuse Bone Graft, Medtronic DBM
Medtronic Spinal and Biologics
Multi-Level Degenerative Lumbosacral Spinal Conditions
04/26
12/26
TLIF, NCT04073563: Transforaminal Lumbar Interbody Fusion

Recruiting
N/A
1017
US, RoW
Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems
Medtronic Spinal and Biologics
Degenerative Disease of the Lumbosacral Spine
04/26
04/28
NCT05856370: The Ailliance Post-Market Clinical Study

Recruiting
N/A
1000
US
Follow-up schedule: pre-operative baseline up to 24-months post-procedure
Medtronic Spinal and Biologics, Medtronic Bakken Research Center
Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma, Spinal Tumor Case
05/31
05/31
Case, Amy Hajari
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
PHINDER, NCT05776225: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection

Recruiting
N/A
200
US
Right heart catheterization (RHC)
United Therapeutics
Interstitial Lung Disease, Pulmonary Hypertension
05/25
06/25
IPF-PRO, NCT01915511: Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Checkmark
Oct 2015 - Oct 2015: 
Recruiting
N/A
3000
US
Duke University, Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
01/28
01/28
Robb, John F
NCT05925712: Aerofit Post Market Investigation

Completed
N/A
56
US
AeroFit Seal-In Liner / Socket, Seal-In Silicone Liner
Össur Ehf
Transfemoral Amputation, Amputation, Skin Health
05/24
05/24
TONE, NCT05971381: Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Completed
N/A
109
US
RECELL® Autologous Cell Harvesting Device, Spray-On SkinTM Cells
Avita Medical
Vitiligo
07/24
01/25
Ament, Jared
3STLIF, NCT04823858: 3Spine Lumbar Fusion Real World Evidence Study

Recruiting
N/A
200
US
Lumbar Interbody Fusion
3Spine, MCRA
Lumbar Spine Degeneration
05/24
08/26
NCT05740176: The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery

Active, not recruiting
N/A
200
US
Anterior Cervical Discectomy and Fusion, ACDF
Synergy Spine Solutions, MCRA
Cervical Degenerative Disc Disease
09/26
12/26
NCT05438719: MOTUS Total Joint Replacement Investigational Device Exemption Study

Active, not recruiting
N/A
158
US
MOTUS Total Joint Replacement
3Spine
Lumbar Spine Degeneration
06/25
06/28
 

Download Options